<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Drug development on FinanClub</title>
    <link>https://finan.club/tags/drug-development/</link>
    <description>Recent content in Drug development on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Tue, 12 Mar 2024 09:02:40 +0000</lastBuildDate><atom:link href="https://finan.club/tags/drug-development/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>CBAY</title>
      <link>https://finan.club/us/cbay/</link>
      <pubDate>Tue, 12 Mar 2024 09:02:40 +0000</pubDate>
      
      <guid>https://finan.club/us/cbay/</guid>
      <description>score:143
Chances: CymaBay Therapeutics, Inc. has submitted the Marketing Authorization Application (MAA) for seladelpar for the treatment of primary biliary cholangitis The New England Journal of Medicine has published detailed results from the RESPONSE Phase 3 trial evaluating seladelpar, showing promising data for the drug Gilead Sciences has proposed to acquire CymaBay for $4.</description>
    </item>
    
  </channel>
</rss>
